Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Trial of Allogenic Adipose-derived Stem Cells (ALLO-ASC-TI) for Lateral Epicondylalgia
KCT0001120Phase 2Recruiting
- Sponsor
- Anterogen Co., Ltd.
- Start
- Mar 2014
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Lateral Epicondylitis (LET) comparing ALLO-ASC-TI with Placebo (2 arms). Primary endpoints: Safety of ALLO-ASC-TI and Efficacy in lateral epicondylalgia. Started Mar 2014; status: recruiting.
02
Drugs
allo-asc
03
Conditions
Lateral Epicondylitis (LET)
Beyond the preview
Go deeper on KCT0001120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001120.